Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neelima Denduluri

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Clinical Breast Cancer|April 7, 2018
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian CancerNeelima Denduluri, Gary H Lyman, Yunfei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera, Janice M Walshe, Douglas R Rosing, et al.
NPJ Precision Oncology|February 16, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersMaysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2018
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused UpdateNeelima Denduluri, Mariana Chavez-MacGregor, Melinda L Telli, et al.
Breast Cancer Research and Treatment|February 26, 2025
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifenStephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO GuidelineLarissa A Korde, Mark R Somerfield, Lisa A Carey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineSaro H Armenian, Christina Lacchetti, Ana Barac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?Jeanne S Mandelblatt, Robert A Stern, Gheorghe Luta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline UpdateNeelima Denduluri, Mark R Somerfield, Mariana Chavez-MacGregor, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Clinical Breast Cancer|April 7, 2018
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian CancerNeelima Denduluri, Gary H Lyman, Yunfei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerChia C Portera, Janice M Walshe, Douglas R Rosing, et al.
NPJ Precision Oncology|February 16, 2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersMaysa M Abu-Khalaf, K Alex Hodge, Christos Hatzis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2016
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluationDavid Miles, David Cameron, Igor Bondarenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2018
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused UpdateNeelima Denduluri, Mariana Chavez-MacGregor, Melinda L Telli, et al.
Breast Cancer Research and Treatment|February 26, 2025
The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifenStephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO GuidelineLarissa A Korde, Mark R Somerfield, Lisa A Carey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineSaro H Armenian, Christina Lacchetti, Ana Barac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?Jeanne S Mandelblatt, Robert A Stern, Gheorghe Luta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2020
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline UpdateNeelima Denduluri, Mark R Somerfield, Mariana Chavez-MacGregor, et al.
Pageof 6